ARCH Venture Partners — Activity | F4ARCH Venture Partners Activity
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Milestone
Paradigm Health partnered with the FDA on a real-time clinical trial monitoring platform.
Paradigm Health
ARCH partner Carol Suh was honored on the San Francisco Business Times 40 Under 40 Class of 2026.
Carol Suh named to San Francisco Business Times 40 Under 40
News
ARCH's Carol Suh was named to the National Venture Capital Association's 2026 List of Rising Stars.
Carol Suh named to NVCA 2026 List of Rising Stars
3 exits· OCT 2025 – JAN 2026Show all
Exit
D-Wave Quantum acquired ARCH-backed Quantum Circuits to accelerate quantum computer development.
Quantum Circuits
Exit
Pfizer acquired ARCH-backed Metsera in $10 billion deal to accelerate obesity drug development.
Metsera
Exit
Bristol Myers Squibb acquired ARCH-backed Orbital Therapeutics and its In Vivo RNA platform.
Orbital Therapeutics
News
TIME and Statista recognized ARCH as a top U.S. venture firm.
TIME and Statista top U.S. venture firm recognition